ORIGINAL ARTICLE 99m Estimating cancer risk from Tc pyrophosphate imaging for transthyretin cardiac amyloidosis a,b c Andrew J. Einstein, MD, PhD, FASNC, Igor Shuryak, MD, PhD, Adam Castan˜o, a b a MD, MS, Akiva Mintz, MD, PhD, Mathew S. Maurer, MD, and Sabahat Bokhari, MD, FASNC Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York Department of Radiology, Columbia University Irving Medical Center and New York- Presbyterian Hospital, New York Center for Radiological Research, Columbia University Irving Medical Center, New York Received Apr 2, 2018; accepted May 10, 2018 doi:10.1007/s12350-018-1307-7 Background. Increasing recognition that transthyretin cardiac amyloidosis (ATTR-CA) is much more common than previously appreciated and the emergence of novel disease-modifying therapeutic agents have led to a paradigm shift in which ATTR-CA screening is considered in high-risk populations, such as patients with heart failure with preserved ejection fraction 99m 99m (HFpEF) or aortic stenosis. Radiation risk from Tc-pyrophosphate ( Tc-PYP) scintigra- phy, a test with very high sensitivity and speciﬁcity for ATTR-CA, has not been previously determined. 99m Methods and Results. Radiation doses to individual organs from Tc-PYP were estimated using models developed by the Medical Internal Radiation Dose Committee and
Journal of Nuclear Cardiology – Springer Journals
Published: May 30, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud